Essential Concepts in Toxicogenomics, Softcover reprint of hardcover 1st ed. 2008
Methods in Molecular Biology Series, Vol. 460

Coordinators: Mendrick Donna L., Mattes William B.

Language: English

105.49 €

In Print (Delivery period: 15 days).

Add to cartAdd to cart
Essential Concepts in Toxicogenomics
Publication date:
277 p. · 15.5x23.5 cm · Paperback

105.49 €

Subject to availability at the publisher.

Add to cartAdd to cart
Essential concepts in toxicogenomics (hardback) book (series: methods in molecular biology)
Publication date:
277 p. · Hardback

The field of toxicogenomics has been growing quickly. This informative and cutting-edge book collects reviews, opinion pieces and case studies from this dynamic field with a focus on its application to pharmaceuticals.

Toxicogenomics and Classic Toxicology: How to Improve Prediction and Mechanistic Understanding of Human Toxicity.- Use of Traditional End Points and Gene Dysregulation to Understand Mechanisms of Toxicity: Toxicogenomics in Mechanistic Toxicology.- Quality Control of Microarray Assays for Toxicogenomic and In Vitro Diagnostic Applications.- Role of Statistics in Toxicogenomics.- Predictive Toxicogenomics in Preclinical Discovery.- In Vivo Predictive Toxicogenomics.- Bioinformatics: Databasing and Gene Annotation.- Microarray Probe Mapping and Annotation in Cross-Species Comparative Toxicogenomics.- Toxicogenomics in Biomarker Discovery.- From Pharmacogenomics to Translational Biomarkers.- Public Consortium Efforts in Toxicogenomics.- Applications of Toxicogenomics to Nonclinical Drug Development: Regulatory Science Considerations.
Includes contributions from experts in fields as diverse as the pharmaceutical industry, biotechnology companies, regulatory agencies, non-profit organizations and academia Covers the many uses of toxicogenomics spanning its predictive application, use in mechanistic analysis, and consideration for risk assessment Discusses the issues that currently limit its universal acceptance including cross species correlations, regulatory uncertainty and biomarker validation